Clinical Trial Update: Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of an anti-PD-1 monoclonal antibody in patients with advanced, trastuzumab-resistant, HER2-positive metastatic breast cancer has completed, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anti-PD-1 Monoclonal Antibody

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-15